BioCentury
ARTICLE | Clinical News

CRLX101 regulatory update

May 4, 2015 7:00 AM UTC

FDA granted Fast Track designation to Cerulean’s CRLX101 to treat metastatic renal cell carcinoma (RCC) in combination with Avastin bevacizumab following progression through 2-3 prior lines of therap...